{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:42Z","timestamp":1790767842505,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001445"],"award-info":[{"award-number":["UL1TR001445"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and hypothesis<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) positive-to-negative kidney transplants require direct-acting antiviral therapy, but the optimal timing and duration remain unclear. We hypothesized that a 14-day prophylactic course of glecaprevir\/pibrentasvir 300\/120\u00a0mg (GLE\/PIB) would be safe and effective at treating donor-derived HCV viremia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a prospective, single-center, single-arm, open-label pilot study. Twenty adult HCV-negative recipients of HCV nucleic acid amplification test positive deceased-donor kidneys (HCV positive-to-negative) received a 14-day course of GLE\/PIB, with the first dose pretransplant. HCV RNA viral load (VL) was monitored on postoperative days (POD) 1, 3, 7, and 13. If VL was undetectable on POD 13, GLE\/PIB was stopped, and if detectable, GLE\/PIB was continued to complete an 8-week course. Surveillance monitoring continued after treatment to ensure sustained viral response (SVR). The primary outcome was efficacy of 14-day prophylactic GLE\/PIB. Secondary outcomes included patient and allograft survival, the incidence, timing, and clearance of HCV viremia, and safety events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven out of 20 subjects (35%) never developed detectable HCV viremia. Only one subject had a detectable, but nonquantifiable, VL on POD 13 and completed an 8-week course. All subjects achieved SVR 12 weeks post-treatment with no relapses through 1-year follow-up. Mean time to undetectable HCV RNA VL was 10.5 (\u00b14.7) days and mean peak VL was 371 (\u00b1715) copies\/mL. Six-month and 1-year patient and allograft survival were 100% and 95%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A 14-day course of prophylactic GLE\/PIB is safe and effective for HCV positive-to-negative kidney transplants and may prevent HCV transmission or significantly reduce the VL for those with detectable transmission, allowing rapid clearance within 2\u00a0weeks.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae271","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:33:14Z","timestamp":1732163594000},"page":"1322-1331","source":"Crossref","is-referenced-by-count":4,"title":["Prophylactic 2-week glecaprevir\/pibrentasvir in hepatitis C positive-to-negative kidney transplantation"],"prefix":"10.1093","volume":"40","author":[{"given":"Rebecca A","family":"Dieter","sequence":"first","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aprajita","family":"Mattoo","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Hotchkis","sequence":"additional","affiliation":[{"name":"University of La Verne Psychology Department, , La Verne, Laverne, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-308X","authenticated-orcid":false,"given":"Ian S","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Grossman School of Medicine NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaina P","family":"Weldon","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Berger","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Ali","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie E","family":"Lonze","sequence":"additional","affiliation":[{"name":"Transplant Institute NYU Langone Health, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025063007571718200_bib1","author":"National data\u2014OPTN"},{"key":"2025063007571718200_bib2","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib3","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1097\/TP.0000000000002323","article-title":"Changes in utilization and discard of HCV-antibody positive deceased-donor kidneys in the era of direct-acting antiviral therapy","volume":"102","author":"Bowring","year":"2018","journal-title":"Transplantation"},{"key":"2025063007571718200_bib4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025063007571718200_bib5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"2025063007571718200_bib6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"2025063007571718200_bib7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies","volume":"37","author":"Schlendorf","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2025063007571718200_bib8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","article-title":"Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study","volume":"4","author":"Bethea","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025063007571718200_bib9","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/hep.30540","article-title":"Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors","volume":"69","author":"Cotter","year":"2019","journal-title":"Hepatology"},{"key":"2025063007571718200_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.14218\/JCTH.2019.00014","article-title":"Transplantation of HCV viremic livers into HCV viremic recipients followed by direct-acting antiviral therapy","volume":"7","author":"Kapila","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"2025063007571718200_bib11","article-title":"HCV NAT positive solid organ allografts transplanted into HCV-negative recipients: a real-world experience","volume":"10","author":"Kapila","year":"2019","journal-title":"Hepatology"},{"key":"2025063007571718200_bib12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors","volume":"19","author":"Kwong","year":"2019","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib13","doi-asserted-by":"publisher","first-page":"e13476","DOI":"10.1111\/ctr.13476","article-title":"Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation","volume":"33","author":"Watson","year":"2019","journal-title":"Clin Transplant"},{"key":"2025063007571718200_bib14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.10960720","article-title":"Trends in discard of kidneys from hepatitis C viremic donors in the United States","volume":"16","author":"Chang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063007571718200_bib15","article-title":"Treatment of HCV-uninfected transplant recipients receiving organs from HCV-viremic donors. Recommendations for testing, managing, and treating hepatitis C","author":"AASLD-IDSA"},{"key":"2025063007571718200_bib16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/j.ajkd.2020.10.017","article-title":"Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes","volume":"77","author":"Molnar","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025063007571718200_bib17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1053\/j.semtcvs.2020.06.045","article-title":"Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors","volume-title":"Semin Thorac Cardiovasc Surg","author":"Smith","year":"2020"},{"key":"2025063007571718200_bib18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N Engl J Med"},{"key":"2025063007571718200_bib19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025063007571718200_bib21","doi-asserted-by":"publisher","first-page":"ofac550","DOI":"10.1093\/ofid\/ofac550","article-title":"A pilot trial for prevention of hepatitis C virus transmission from donor to organ transplant recipient with short-course glecaprevir\/pibrentasvir","volume-title":"Open Forum Infect Dis","author":"Ramirez-Sanchez","year":"2022"},{"key":"2025063007571718200_bib22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/ajt.15583","article-title":"Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: a unique complication in the DAA era","volume":"20","author":"Kapila","year":"2020","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2025063007571718200_bib24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label non-randomized study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025063007571718200_bib25","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1111\/ajt.16747","article-title":"Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants","volume":"21","author":"Gupta","year":"2021","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.10.006","article-title":"Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study","volume":"24","author":"Aleyadeh","year":"2024","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib27","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1111\/ajt.15582","article-title":"Lessons from the real world: HCV-infected donor kidney transplantation as standard practice","volume":"19","author":"Durand","year":"2019","journal-title":"Am J Transplant"},{"key":"2025063007571718200_bib28","doi-asserted-by":"publisher","first-page":"e13775","DOI":"10.1111\/tid.13775","article-title":"Caregiver exposure to hepatitis C virus following transplantation with hepatitis C viremic donor organs: a case series","volume":"24","author":"Kim","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"2025063007571718200_bib29","article-title":".","author":"MAVYRET","year":"2024"},{"key":"2025063007571718200_bib30","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.7326\/M23-2682","article-title":"Two-week direct-acting antiviral prophylaxis for kidney transplantation from donors with hepatitis C viremia to recipients without hepatitis C viremia: a small uncontrolled trial","volume":"176","author":"Desai","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025063007571718200_bib31","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/hep.26905","article-title":"Is genotype 3 of the hepatitis C virus the new villain?","volume":"59","author":"Goossens","year":"2014","journal-title":"Hepatology"},{"key":"2025063007571718200_bib32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13318-017-0428-8","article-title":"Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers","volume":"43","author":"Lin","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2025063007571718200_bib33","doi-asserted-by":"publisher","first-page":"20543581211033496","DOI":"10.1177\/20543581211033496","article-title":"Expanding the deceased donor pool in Manitoba using hepatitis C-viremic donors: program report","volume":"8","author":"Cuvelier","year":"2021","journal-title":"Can J Kidney Health Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae271\/60935982\/gfae271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/7\/1322\/60935982\/gfae271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/7\/1322\/60935982\/gfae271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:57:25Z","timestamp":1751284645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/7\/1322\/7905895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae271","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,11,20]]}}}